Authors: Teddy Hoppe¹, George Kenefati², Gelana Tostaeva³, Ana Radanovic⁴, Daniel Hașegan⁵, Paul Brezovsky III⁶, Fargol Yeganeh Fathi^4,7, Nayanika Biswas⁸, Saar Lively⁹, Louis Zhao^10,11, Margot Hanley^12,13, and Charles Rodenkirch¹⁴

Affiliations: ¹Nathan Kline Institute; ²NYU Langone Health; ³Icahn School of Medicine at Mount Sinai; ⁴Weill Cornell Medicine; ⁵NYU Grossman School of Medicine; ⁶Qapita; ⁷Burke Neurological Institute; ⁸Barclays; ⁹Sero Labs; ¹⁰Radical Health; ¹¹Columbia University; ¹²Netholabs; ¹³Cognitive Futures Lab, Duke University; ¹⁴Sharper Sense

All authors are members of the NeuroNYC team. This report is an independent NeuroNYC publication. Affiliations are provided for identification only; the authors’ employers and affiliated institutions did not necessarily sponsor, review, or endorse the report.

01

NeuroNYC Resources

Ecosystem Tracker

Greater New York is home to a world-class neurotechnology ecosystem. Our tracker catalogs regional companies, clinics, laboratories, and investors.

Events Calendar

Explore events that connect the regional neurotechnology community and foster collaboration, communication, and shared learning.

NY Neuro News

Follow recent neurotechnology news from across Greater New York.

Latest Neurotech Papers
Track recent neurotechnology publications from researchers across the region.

Local Neurotech Jobs
Find neurotechnology roles at regional companies, laboratories, health systems, and partner organizations.

Local Neurotech Products
Explore neurotechnology products developed or commercialized by organizations in Greater New York.

Local Neurotech Clinical Trials
Review registered neurotechnology studies associated with regional institutions and investigators.

Join NeuroNYC

Join the Community
Sign up to access our Slack channel and free events.

Volunteer
Join the team and get priority access.

Donate
Help us advance neurotechnology and unlock its benefits for the Greater New York region.

Purpose and methodology

Purpose. NeuroNYC prepared this report to describe the scale, composition, activity, and development needs of the Greater New York neurotechnology ecosystem. It consolidates public information on companies, clinical programs, laboratories, funders, publications, clinical trials, policy, and selected ecosystem relationships. The report is descriptive rather than a census, market-sizing study, investment-performance analysis, or comparative ranking of regions.

Geographic scope and data cutoff. “Greater New York” includes New York City, Long Island, Westchester and the lower Hudson Valley, northern and central New Jersey, Princeton, southwestern Connecticut, and New Haven. Unless a figure states otherwise, the reporting period covers activity identified through July 2026.

Inclusion and exclusion. An organization or program was included when it was active at the cutoff date, had a documented operational, research, clinical, investment, or organizational presence in the region, and worked directly in neurotechnology. The scope includes brain–computer interfaces, neuroprostheses, neuroimaging, neurofeedback, neuromodulation, neuroinformatics, neural sensing and electrophysiology, rehabilitation technologies, and closely related computational or clinical platforms. Entities with no verified regional presence, inactive or discontinued entities, general neuroscience activity without a material technology component, and organizations supported only by undated or unverifiable claims were excluded.

Evidence and interpretation. Counts are based on the companies, programs, laboratories, funders, publications, and trials included in the analysis, not on a claim of complete regional coverage. Categories can overlap because a single entity may span multiple technologies, indications, markets, or functions. Public sources favor organizations that disclose activity and therefore underrepresent private, early-stage, discontinued, or confidential work. Financing mandates do not establish deployed capital; regulatory or trial status does not establish commercialization, reimbursement, utilization, or clinical impact. Findings are separated from proposed economic-development interventions in the conclusion.

02

Executive summary

Central thesis

Greater NY is not converging on a single winning modality. It is becoming a systems market where sensing, stimulation, imaging, AI, clinical workflow, and longitudinal data are bundled around specific use cases.

The bottleneck is shifting from invention toward execution: evidence generation, multicenter operations, reimbursement, manufacturing, and deployment architecture.

Scale, institutional depth, and the regional path from discovery to deployment

Figure 1. Core ecosystem counts and geographic scope.

Greater New York comprises New York City, Long Island, Westchester and the lower Hudson Valley, northern and central New Jersey, Princeton, southwestern Connecticut, and New Haven. The mapped ecosystem is large enough to support a regional economic-development strategy, but the central challenge is conversion: moving scientific and clinical capability into validated products, durable companies, specialized jobs, and locally retained production.

1. Scale and composition. The analysis maps 39 companies, 47 clinical programs, 59 laboratories, and 48 funder organizations across the region. The breadth is economically relevant because it creates multiple entry points for company formation, clinical adoption, investment, and specialized services.

2. Institutional and research concentration. Thirty-eight of the 59 laboratories are classified as clinical or translational, and the regional cohort produced 960 query-defined neurotechnology publications in 2025. The principal opportunity is to connect this research base more consistently to product development and commercialization.

3. Commercial maturity and financing. The company base spans active commercial operations, development-stage ventures, and organizations in transition, while disclosed financing is concentrated in a limited number of large transactions.

4. Clinical translation and access. The 47 clinical programs provide an established base of clinical-trial activity and care across academic, independent, rehabilitation, and virtual-first settings, but only eight explicitly identify an at-home, remote, virtual, telerehabilitation, or home-rental pathway. Product authorization, reimbursement, workflow integration, and patient access remain separate constraints.

5. Constraints on regional scale-up. The evidence points to gaps in translational infrastructure, pilot and procurement pathways, shared clinical validation, specialized manufacturing, founder-investor connectivity, workforce development, regulatory and reimbursement support, and neural-data governance. These are candidate intervention areas rather than effects directly measured by the dataset.

Figure 2. Neurotechnology publications in 2025 and cumulative clinical-trial counts.

Figure 3. State rankings by number of neurotechnology entities.

Figure 4. Structural shifts in the regional neurotechnology market.

03

NeuroNYC community

Community metrics as of July 2026

LinkedIn Followers: 3,774

Email List Subscribers: 1,393

Slack Channel Members: 476

Mailing List Affiliation Breakdown

04

Companies: operating status and maturity

Public evidence distinguishes active commercial operation from development, transition, and unresolved status.

Figure 5. Publicly verified operating-status composition of the 38 companies included in this analysis.

Regulatory status is product- and indication-specific. Breakthrough Device designation, investigational device exemption activity, trial registration, hospital use, and “clinical-grade” claims do not constitute marketing authorization. Likewise, authorization alone does not establish commercial launch, reimbursement, clinical adoption, or approval across an entire product portfolio.

05

Companies: technology and market composition

The company cohort is clinically weighted and technologically heterogeneous.

Figure 6A. Technology representation within the company cohort.

Figure 6B. Market orientation within the company cohort.

AI and computational methods, diagnostics, electrophysiology, neural interfaces, neurofeedback, imaging, stimulation, rehabilitation, and digital interventions all appear in the company cohort. Medical and clinical applications constitute the largest market orientation, with research and pharmaceutical uses and consumer and performance applications forming meaningful secondary segments. Category assignments reflect public company positioning and may overlap.

06

Companies: architecture, function and indication

The regional product landscape spans sensing, interpretation, intervention, and assistance rather than one dominant device class.

Figure 7A. Company architecture by functional role.

Figure 7B. Company representation by indication and use case.

The portfolio contains hardware, software, research tools, and integrated systems. Sensing and analysis frequently co-occur, while intervention, restoration, and procedural guidance occupy smaller but distinct segments. Condition tags reflect stated positioning, not epidemiology, demand, or revenue.

07

Companies: selected 2025–2026 milestones

Clinical, financing, regulatory, and organizational developments through July 2026

Figure 8. Selected completed and dated company milestones through July 28, 2026.

08

Clinical programs: modality and provider structure

Listed care spans academic health systems, independent practices, rehabilitation, and virtual-first models.

Figure 9A. Technology modalities represented across 47 listed clinical programs.

Figure 9B. Listed clinical programs by provider type.

Academic health systems dominate invasive, surgical, imaging, epilepsy, movement-disorder, and complex rehabilitation modalities. Independent practices are more visible in outpatient TMS, neurofeedback, psychiatric care, and selected remote services. Counts describe programs, not clinicians, procedures, patients, capacity or quality.

09

Clinical programs: condition × modality

Different indications engage distinct technology portfolios and care settings.

Figure 10A. Condition-by-modality representation among the clinical programs included in the analysis.

Psychiatric conditions, movement disorders, epilepsy, pain, and stroke/brain injury show broad listed modality representation. Implantable and surgical systems cluster in academic programs; neurofeedback and outpatient noninvasive stimulation are more widely represented among independent providers.

Figure 10B. Most frequently listed neurotechnology treatments and conditions in Greater New York.

10

Clinical access: remote delivery and reimbursement

A listed technology becomes accessible only after multiple product, coverage, and workflow gates are passed.

Figure 11. Modality-level reimbursement architecture.

Eight of 47 listed programs explicitly mention at-home, remote, virtual, telerehabilitation or home-rental delivery.

Mature procedural categories—including spinal cord stimulation and selected uses of deep brain stimulation, transcranial magnetic stimulation, electroencephalography, and focused ultrasound—have comparatively well-defined reimbursement pathways. External vagus nerve stimulation, prescription digital therapeutics, nonstandard stimulation protocols, wellness products, and investigational brain–computer interfaces remain fragmented, product-specific, or restricted to research settings. Coverage ultimately varies by product, indication, payer, billing code, documentation, and provider.

11

Capital: mandates and observed deployment

What public data reveal—and do not reveal—about regional capital

Figure 12. Neurotechnology relevance of 48 listed funder organizations.

Thirteen funders are classified as specialist or mission-driven, 15 have active thematic exposure, and 20 are opportunistic or adjacent. Forty-four are oriented toward medical or research applications. These classifications describe publicly stated mandates and documented activity; they do not measure capital availability, deployment, or investment performance.

Figure 13. Concentration of recent disclosed capital in large, marquee neurotechnology transactions.

Figure 14. Investable architectures across the regional neurotechnology landscape.

Figure 15. Most active investors with a documented presence in the regional neurotechnology ecosystem.

12

Ecosystem relationships: origins, collaboration and deployment

A documented network of institutional origins, collaborations, and deployment relationships

Figure 16. Selected publicly documented institutional and commercial relationships.

13

Laboratories: a broad, platform-heavy research base

The 59-lab cohort combines computation, interfaces, recordings, imaging, rehabilitation, and stimulation.

Figure 17. Technology footprint of the 59-laboratory portfolio.

Thirty-eight listed labs are coded clinical/translational and 21 foundational or methods-oriented. AI/computation appears in 37 descriptions; BCI and electrophysiology in 17 each; neuroimaging in 16; rehabilitation/robotics in 14; and implantable or invasive interfaces in 13.

Figure 18. Conditions most frequently represented in the regional laboratory cohort.

Figure 19. Institutions with the largest number of neurotechnology-focused laboratories in the curated cohort.

14

Research output and clinical-trial activity

2025 reached a query-scoped publication peak and a higher trial-start count than 2024.

Figure 20. Comparable annual views of clinical-trial starts and 2026 registrations. Year-to-date data are current through July 21, 2026.

960 publications in 2025: 11.9% above 2024 and 25% above 2023.

Figure 21. Annual neurotechnology publication count for the query-defined regional cohort.

15

Clinical-trial momentum

Recent movement in emerging categories alongside established trial modalities

Figure 22A. Directional momentum by technology category.

Figure 22B. Directional momentum by indication category.

16

Institutional specialization and the frontier/backbone distinction

Research and trial leadership is distributed across institutions with differentiated modality and clinical strengths.

Figure 23. Active pipelines and 2025-2026 trial starts for the largest institutional cohorts.

NYU Langone, Columbia/NYSPI, Yale, and Mount Sinai have the largest recent-start counts in the supplied institution table. This reflects registry participation and source normalization, not exclusive leadership, quality or ownership of each study. Multisite trials can involve more than one institution.

Established base: imaging, EEG, TMS, and tES have substantial historical trial volume. Emerging categories: closed-loop, peripheral/autonomic, and focused-ultrasound protocols show recent directional momentum.

17

Integrated synthesis: technology across verticals

The ecosystem is not vertically uniform; technologies appear differently in research, products, funding mandates, and care.

Figure 24. Technology representation within each ecosystem segment: companies, clinical programs, laboratories, and funders.

The heat map compares normalized representation within heterogeneous cohorts. AI/computational work is highly represented in lab and company descriptions. Noninvasive and implanted stimulation have stronger downstream clinical representation. Diagnostics and digital-health categories receive substantial explicit funder attention.

Figure 25. Ongoing structural changes across the regional neurotechnology ecosystem.

18

Integrated synthesis: conditions across stages

Research, company, trial, and care portfolios emphasize different clinical and functional targets.

Figure 26. Within-stage representation of conditions and use cases.

Psychiatric categories are strongly represented in recent trial starts and listed clinical programs. Movement disorders, epilepsy, pain, and stroke/brain injury have substantial clinical-program representation. The lab portfolio emphasizes aging/dementia, motor/paralysis/SCI, psychiatry, and sensory/speech work, while many labs remain platform-oriented rather than condition-specific.

19

Policy and public infrastructure

Neural-data rules and selected public investments across the region

Figure 27. Comparison of neural-data policy across the core states in the regional cohort.

20

Conclusions: from evidence to action

Economic-development implications of a diverse regional neurotechnology base

Figure 28. Evidence-mapped strengths, emerging patterns, and binding unknowns.

Greater New York contains a broad neurotechnology base spanning scientific platforms, clinical programs, product companies, and multiple capital sources. The region does not converge on one modality: sensing, stimulation, imaging, computation, rehabilitation, surgical systems, and software coexist around different use cases.

What the dataset supports. Greater New York has a substantial research and clinical base, a heterogeneous company portfolio, and multiple forms of capital exposure. It also shows uneven commercial maturity, limited visibility into deployed capital, fragmented access pathways, and incomplete public evidence on the conversion of regional science into scaled products and retained economic activity. These findings establish where additional measurement and coordination are warranted; they do not by themselves prove that any specific public intervention will produce a given economic outcome.

Economic-development implications. For NYCEDC and related stakeholders, the evidence suggests testing interventions that reduce the friction between discovery, validation, adoption, and regional scale-up. Candidate priorities include translational infrastructure; pilot and procurement pathways with health systems and public agencies; shared clinical-validation capabilities; specialized manufacturing and supply-chain development; stronger founder–investor connectivity; workforce programs spanning technical, clinical, regulatory, and manufacturing roles; regulatory and reimbursement support; and practical neural-data governance. These interventions align with the city’s broader emphasis on commercializing research, expanding specialized space, and building an accessible life-sciences workforce, but their design should be neurotechnology-specific and evaluated against measurable conversion outcomes.

Measurement agenda. The next phase should track company formation and survival, follow-on financing by stage, pilots and procurement contracts, regulatory milestones, clinical-validation timelines, manufacturing location, job creation and occupational mix, reimbursement progress, and the share of regional intellectual property that becomes locally scaled activity. This would allow future editions to distinguish ecosystem breadth from economic conversion and to assess which interventions are producing durable regional value.

Figure 29. Evidence-mapped gaps in the Greater New York neurotechnology ecosystem.

Figure 30. Priority actions for ecosystem stakeholders.

Who are we? We are NeuroNYC, and our mission is to cultivate the neurotech community within the NYC area. We bring together founders, researchers, clinicians, investors, operators, artists, and policymakers across the entire neurotech ecosystem, spanning BCIs, neuromodulation, digital health, AI-driven neuroscience, and more.

Our goal is simple: build a high-signal, human-scale community that helps neurotech move from the lab to real-world impact.

🍂 Recap:

• NeuroNYC x Precision Neuroscience Recap: Over 100 researchers, operators and neurotech enthusiasts joined us last Thursday for an evening on building a career in BCI. Precision’s Chief People Officer Joel Greengrass shared his path into the field and advice on networking and interviewing with intention, followed by a panel with Olivia Conroy, Jake Sabia and Eva Larsen, moderated by Jeremy Zadek. Thank you to Brown Rudnick LLP for hosting, the Precision team for their candor, Patricia Fernandez and Jeremy Zadek for partnering with us, and our organizers Ana Radanovic, Gelana Tostaeva and our volunteers.

🗓️ Events:

• No confirmed upcoming event but keep your eye out for a potential happy hour announcement!

• Check out our LinkedIn to stay updated:https://www.linkedin.com/company/neuronyc 

Looking further ahead:

• New York Brain-Computer Interface Symposium, November 5th & 6th:Join Mount Sinai BioDesign for NYBCI, a global symposium returning to New York City for two days of bold keynotes, panels, and breakout sessions led by the world’s foremost experts in neuroscience, surgery, neurotech, and regulation in the brain-computer interface world. Register here. 

• Keep an eye out for the announcement of our second annual NeuroBall, happening in December! 

🧠 NeuroNYC News:

• NeuroNYC Fellowship, Spring 2027: Thanks to a grant from the FJ Brotherton Charitable Trust, we’re launching a six-week program pairing twelve early-career neurotech researchers, clinicians and founders with senior mentors from our network, and we’d love to hear from you if you’re interested in applying to be a fellow or a mentor. Deadline is January 1st: https://forms.gle/aHCxkDbEgsBkY7z2A

🗽 Neurotech News in NYC:

• Ackman Oxman Institute (AOI): Bill Ackman and Neri Oxman have launched the Ackman Oxman Institute (AOI), a Manhattan nonprofit focused on brain research, neurosurgery, rehabilitation and longevity, seeded with roughly $400M in Pershing Square stock and housed in a 400,000-square-foot biotech facility on West End Avenue. With BCIs, device development and human trials in scope, plus its own venture arm, it’s one to watch for the NYC translational pipeline. Read more here.

• Mount Sinai: A Nature study led by Renata Batista-Brito at the Icahn School of Medicine identified an extremely rare population of cortical neurons that can synchronize activity across the brain and actively promote sleep, challenging the century-old view that sleep is driven only by deep brain structures. Read more here.

• NYU Langone (neurofeedback for PTSD): NYU Langone, the only U.S. site in the pivotal trial behind Prism’s FDA clearance, now offers the amygdala-targeted EEG neurofeedback device to PTSD and depression patients and is running further studies in adults, adolescents and ADHD. Read more here.

• OpenBCI joins AWEAR: Brooklyn-based OpenBCI has come on as an investor and partner in AWEAR, a startup building brain-wellbeing technology. Read more here.

🔎 For the curious souls who want to read more neurotech newsletters:

• Neurotech Notables by Naveen Rao: For those curious about keeping up with the fast-advancing neurotechnology landscape, by Naveen Rao is the biweekly newsletter covering everything moving in neurotech, including funding, breakthroughs, industry shifts, and the deals you’ll be hearing about next:  

NEUROTECH FUTURES

The #1 neurotechnology industry newsletter in the world. Join our ecosystem for news, analysis, jobs, events, & more!

By Naveen Rao

• Reccy Neuro: Chay Carter and Max Kelly have co-founded Reccy Neuro, a platform providing personalized recruiting for neurotech jobs. Check out their newsletter:

The Neurotech Newsletter

The Neurotech Newsletter, brought to you by Carter Sciences. All the Neurotech News and Deep Dives right, plus some interviews and opinion pieces. I work as an advisor, connector and researcher across the industry and share most of my findings here.

By Chay’s Neurotech Newsletter

• Dragonfly 44 Capital Newsletter: Michael Brotherton and Joe Hashmall of Dragonfly 44 Capital put out a monthly newsletter on neuroscience capital and regulatory moves as well as a daily update that highlights 4 newsworthy articles of the day. You can sign up for both in your inbox here: dragonfly44.capital/insights

Want something in the next newsletter? Send it my way: fay4004@med.cornell.edu

Until next time,

Fargol Yeganeh Fathi

Head of Academic Partnerships @ NeuroNYC

Who are we? We are NeuroNYC, and our mission is to cultivate the neurotech community within the NYC area. We bring together founders, researchers, clinicians, investors, operators, artists, and policymakers across the entire neurotech ecosystem, spanning BCIs, neuromodulation, digital health, AI-driven neuroscience, and more.

Our goal is simple: build a high-signal, human-scale community that helps neurotech move from the lab to real-world impact.

🌷 Recap:

• Thank you to everyone who joined our 2nd Annual NeuroNYC Neurotech Summit, where we unveiled the State of Neurotech in Greater NY (2025–2026) report. The big picture: 2025–2026 marked a translation inflection point, with NY’s academic institutions specializing in specific topics rather than competing. Capital told a barbelled story (a few large rounds atop many sub-$5M deals, with only 13 of 48 regional funders doing dedicated neuro underwriting), and the durable moat is shifting from any single sensor toward “device + data + workflow.“ The ecosystem’s biggest gaps are translational, not scientific, which is why 2027–2030 shapes up as a readout period, where the current pipeline either crosses into repeatable care and scalable businesses, or doesn’t.

• We also stayed busy with our NeuroNYC GP/LP Happy Hour, a curated evening for investors across neurotech, mental health, brain health, and neurodegenerative disease (Emerging Managers included), and partnered on the NYC Neuromodulation Conference(Congratulations to our advisor Dr. Marom Bikson and the City College of New York team on the great success!), where we hosted a student social hour and a Women in Neurotech event. Great to bring both the investor community and the next generation of researchers together.

🗓️ Events:

• NeuroNYC x Precision Neuroscience Event, September 10th: Are you a student or an early-career professional looking to break into the neurotech industry? Save the date for an evening on building your career in brain-computer interfaces with Joel Greengrass, Chief People Officer at Precision Neuroscience. Keep an eye out for more details on our LinkedIn.

• Mental Health Build, September 25th: Are you an engineer, MBA student, or rising professional looking to break into mental or brain health, or a company hunting for your next great hire? Then this one’s for you. GreyMatter has teamed up with Julia Bernstein’s #HiringFriday to connect the sharpest builders in the space with the talent to help them grow. Two ways to take part:

  • Talent (apply by September 7th): Engineers, MBA students, and rising professionals can apply (click) to attend and find their next opportunity in the space.

  • Companies (apply by August 14th): Teams building in mental health, health tech, or neurotech can apply (click) to meet their next great hire.

• Check out our LinkedIn to stay updated: https://www.linkedin.com/company/neuronyc 

Looking further ahead:

• New York Brain-Computer Interface Symposium, November 5th & 6th: Join Mount Sinai BioDesign for NYBCI, a global symposium returning to New York City for two days of bold keynotes, panels, and breakout sessions led by the world’s foremost experts in neuroscience, surgery, neurotech, and regulation in the brain-computer interface world. Register here. 

🧠 NeuroNYC News:

• 📣 NeuroNYC is looking for a volunteer! Are you passionate about social media strategy, content, and community engagement? We’re looking for someone to manage and grow our Instagram and LinkedIn presence. 📩 Email us: hello@neuro-nyc.org

🗽 Neurotech News in NYC:

• Sero Labs: Our very own Saar Lively, president/co-founder of NeuroNYC, has launched Sero Labs, a Brooklyn-based non-invasive neurotechnology company applying the science of human connection.

• Sharper Sense: Sharper Sense, founded by NeuroNYC chair/co-founder Charlie Rodenkirch, was awarded an Empire State Development (NYSTAR) Innovation Matching Grant to support commercialization.

• Precision Neuroscience: Precision Neuroscience appointed John Donoghue, a pioneer of brain-computer interfaces, as Scientific Advisor.

• Feinstein Institutes (Northwell): Spark Biomedical and the Feinstein Institutes published a first-in-human study showing their non-invasive tAN technology enhances platelet function.

🔎 For the curious souls who want to read more neurotech newsletters:

• For those curious about keeping up with the fast-advancing neurotechnology landscape, Neurotech Notables by Naveen Rao is the biweekly newsletter covering everything moving in neurotech, including funding, breakthroughs, industry shifts, and the deals you’ll be hearing about next:

NEUROTECH FUTURES

The #1 neurotechnology industry newsletter in the world. Join our ecosystem for news, analysis, jobs, events, & more!

By Naveen Rao

• Chay Carter and Max Kelly have co-founded Reccy Neuro, a platform providing personalized recruiting for neurotech jobs. Check out their newsletter:

The Neurotech Newsletter

The Neurotech Newsletter, brought to you by Carter Sciences. We share bi-weekly updates on Funding, Regulatory, Clinical, Launches and Hiring news. Subscribe for full articles and analysis

By Chay’s Neurotech Newsletter

Want something in the next newsletter? Send it my way: fay4004@med.cornell.edu

Until next time,

Fargol Yeganeh Fathi

Head of Academic Partnerships @ NeuroNYC

Neurosoft has shown impressive growth since their founding in 2020, most recently closing a $7.5 million oversubscribed seed round in May. In February, they announced a partnership with implantable BCI firm Science Corp to utilize the Silicon Valley group’s full stack of clinical-grade neural recording tools. Right before closing their seed round, they won a grant from the Swiss AI Initiative to access the globally-ranked, hydro-powered supercomputer Alps, which they’ll use to accelerate the training of their neural decoding models.

This spring, Neurosoft opened a second office in New York. We reached out to their co-founder and CEO, Nicolas Vachicouras, for an interview about the recent move, their headlines from earlier this year, and developments to look forward to from the group. Below is a transcript of our conversation, edited for clarity.

Hey Nicolas, thanks for taking the time to talk.

What prompted Neurosoft’s move to New York? Are there any exciting collaborations you’re planning or resources you hope to tap in New York in the future?

We’re based in Switzerland, and we wanted to have an office and a presence in the US, because it’s our first market in terms of regulatory pathway. From a fundraising perspective, I also feel like there’s more capital and more willingness to invest in this field versus in Europe, which is a bit more risk-averse.

This is the general explanation for having a presence in the US, but we really needed to have a presence in New York for a few other reasons. First of all, convenience in terms of time zones, because we still have a large team in Geneva, Switzerland, and we wanted to make sure the US and Swiss teams could work closely enough, because a 9-hour time difference with California can be harder to manage. And more importantly, I really feel like there is a growing ecosystem here in New York. If we look at implantable BCI companies, there are not that many compared to non-invasive BCI startups, but two of them, Synchron and Precision, are here in New York. So for us, it made a lot of sense. Then if you look at the broader neurotech field, there’s Kampto Neurotech, OpenBCI, and Meta Reality Labs here in New York, and in general, if we look at the broader coast, between here, Connecticut, and Boston, with companies like Axoft or Neurable, it’s overall a good place to be.

There are also good incentives from the state of New York. We are currently talking with them to see how we can leverage that. I feel like there’s a large push to try to attract life science companies beyond neurotech. And by talking to some of our investors, there seems to be more neurotech companies starting here in New York. So I feel like it’s an overall good location.

Finally, we also see a very strong pool of talent, and very good hospitals here with Mount Sinai, Langone, and others. That’s also very important to us.

New York State, and City, have put a lot of effort into growing the life sciences and tech scenes here. I’m reminded of EmpireAI, the state’s AI initiative that operates a supercomputer in Buffalo, because of the supercomputer you’re using through the Swiss AI initiative to train your neural decoding models.

Do you feel Neurosoft is ahead of the curve on neuroAI? Do you imagine being leaders in that field?

I wouldn’t say we’re ahead of the neuroAI curve now, but that’s definitely our objective: to be able to lead this field thanks to our scalable brain interface. There’s a lot of neuroAI happening in the non-invasive space, but there is still a lot to be done on the implantable side. The main bottleneck there is a huge lack of high-quality brain data, which we believe we can solve with our technology. This is actually one of the things we want to develop in New York, as we’re starting to gather more data.

Are you seeking more machine learning engineers and researchers here in New York? And if so, are you finding there to be a good applicant pool here?

We made our first hire recently, Florence Lee, who is a senior embedded systems engineer here. As you might have seen, we are collaborating with Science Corp, based in California, and she is helping with the hardware integration of Science components with our brain interfaces built in Switzerland. And indeed, one of our open positions is on the ML/AI side, and we plan to grow that team even more in the future. We believe there’s an overall strong pool of talent for both hardware and software engineers, in both neurotech (thanks to Precision and Synchron), and more broadly in AI, with strong universities here.

Why did you choose New York over a city like Boston, where the universities, hospitals, and life sciences ecosystem are comparable?

People always ask me: ‘why not Boston?’. They understand why we chose the East Coast, but not why New York versus Boston. I feel like Boston has really been more in biotech and less so in neurotechnology. It’s only recently in the past few years that there have been spinoffs from MIT and Harvard in neurotech. Before then, I feel like the big hubs were really mostly in New York, Texas, and California.

How do you find the East Coast compares culturally with those hubs, and Europe?

When I think of investors, I always talk about this gradient, where you have on one extreme the risk-averse Europeans, then you have the East Coast, and then you have the very ambitious West Coast.

I give this example when people ask me the difference between California and Europe: I was pitching one day to a Swiss-German investor in the morning, and he was asking me what our revenue will be two years from now. That afternoon, I was talking to someone in San Francisco, asking me if in twenty years, they could drive their Tesla with their brain. So that tells you everything you need to know.

I really like Europe. I think there’s a great environment, great innovation, and really, really good talent. But when I think about why there’s still this big difference around risk perception and ambition, I believe it’s a mentality issue more than anything.

Do you think that gradient is the same for the public perception of neurotech — do you find people themselves are less receptive of neurotech in Europe?

For sure. My co-founder was in California a few months ago and told me, “I was stopped at a red light, and every car waiting there had no driver.” You won’t see that in Switzerland yet. In general, Europeans tend to view advanced technologies through the lens of risk: focusing more on the negatives than the positives, when there are always both. In the US, the emphasis falls on the positives. There are exceptions, of course: I’ve met great people who embrace risk in Europe and Switzerland. Our lead investor is a great example: they are European, even though their founder grew his company in the US before coming back, so he’s heavily US-minded. But yes, I see this gradient across regulation, public perception, and funding alike.

Speaking of the West Coast, are you excited to be working with Science Corp, a group in the heart of things in Silicon Valley?

Yes, for sure. I have known Max Hodak for many years now and have followed his work at Science Corp, and it’s one of these companies where I really believe in the technologies they’re building. There are different approaches and technologies to building BCIs, and in particular the backend electronics required for a fully implantable system, and Science Corp are working on the right technology stack and form factors that I would have explored if I had the same amount of money as they have.

And then their team is really excellent. We are really happy with the people we’re working with there. So yes, definitely exciting. And, finally, Max helped me a lot to understand the difference between the US investor mindset, versus European ones. For me, it was a big clash. When I started pitching to California investors, I thought we were speaking a different language. So it was helpful.

I noticed the parallels between Neurosoft’s approach and Science Corp’s — it seems, just in watching interviews of Max, that he cares deeply about creative and feasible solutions to bio-integration, for example. Are you actively working with Science day-to-day?

Yes, our R&D team has regular meetings with them and daily email exchanges. We are really working hand-in-hand together to combine technologies.

On the note of Silicon Valley, some frontier AI labs recently opened up here in New York City. Do you see any future neuroAI collaborations happening here?

Yes. We recently announced our VP of Neuro AI hire, who is putting in place our AI strategy, and part of it is to set up collaborations with either researchers or companies who are actively in the neuroAI field, if we think that there are synergies. I cannot tell you any names for now, but we are definitely interested in collaboration in that area.

NeuroAI is something that NeuroNYC is very interested in covering and being an active part of. I think I had seen you say in a past interview that BCI and AI are becoming one and the same, that to be ahead in one is to be ahead in the other.

I know there’s a big hype around AI in general, but historically AI has always played a very important role for BCIs, in helping decode brain activity. And there is also a lot of interest in both directions: not only how AI can improve neurotech, but also the opposite: how what we learn from the brain can help improve AI. This loop is super interesting from a broader perspective, and I am also personally interested in how these tools can help us better understand biological intelligence and cognition.

Thanks Nicolas! Really appreciate the time.

Appreciate it, and thanks for reaching out.

Share

Who are we? We are NeuroNYC, and our mission is to cultivate the neurotech community within the NYC area. We bring together founders, researchers, clinicians, investors, operators, artists, and policymakers across the entire neurotech ecosystem; spanning BCIs, neuromodulation, digital health, AI-driven neuroscience, and more.

Our goal is simple: build a high-signal, human-scale community that helps neurotech move from the lab to real-world impact.

May and June Recap:

• Thank you to everyone who joined us during NY Tech Week events. We loved bringing the neurotech community together in a fun, informal setting, with a little extra Knicks energy mixed in.

• Margot Hanley and I (Fargol Yeganeh Fathi) alongside some of our NeuroNYC advisors and friends attended the 2026 Berkshires Brain Summit last week organized by Dragonfly 44 Capital and GreyMatter. This summit brings together leading investors, entrepreneurs, scientists, clinicians, and strategic partners for an intimate gathering focused on the future of neuroscience, neurotechnology, and mental health. Hosted at The Thyme in the Berkshires, the summit combined thoughtful discussion, scientific insight, and retreat-style connection across the brain health ecosystem.

Events:

• 3rd Annual Innovation in Neurosciences, July 17th: A symposium bringing together neuroscience leaders, acute care clinicians, and industry teams to explore the latest advances in cerebrovascular care, neuroendovascular surgery, neurology, neurosurgery, neuroimaging, neurotechnology, and neuropharmacology. Register here: https://www.eventbrite.com/e/3rd-annual-nys-in-innovation-in-neurosciences-tickets-1985453244100
  

• NeuroNYC GP/LP Happy Hour, July 20th: This is a curated evening for investors who are active in or exploring the neurotech space, including invasive and non-invasive neurotechnology, mental health, brain health, brain-computer interface (BCI), and neurodegenerative disease. If you’re an investor in neurotech, mental health, brain health, or neurodegenerative disease, emerging managers included, we’d love to see you there. Space is limited and subject to vetting. Register here: https://luma.com/qlytyu5m

• NeuroNYC’s 2nd Annual NY Neurotech Summer Summit, July 21st: Hosted by Cooley LLP, the Summit convenes leaders from neurotech companies, clinics, labs, funds, advocacy, policy, and media to advance the neurotech industry in Greater New York and expand local access to its benefits. It is a premier opportunity to build leadership-level connections and catalyze collaboration across the NY ecosystem and nationally. This is an invite-only event. If you or an industry peer would be a valuable addition to this conversation, please submit a nomination form here: https://docs.google.com/forms/d/e/1FAIpQLSfj5QjRncyrrUshgkW-6ilgmI1YYx-KH4D0_5S6tAI0X-ICYg/viewform?usp=publish-editor

• NYC Neuromodulation Conference, July 30 to August 3: NeuroNYC is an official partner of the conference and is offering an exclusive community discount. NeuroNYC will also host a student social hour and a Women in Neurotech event during the conference. Register with code NEURONYCX26: https://neuromodec.org/2026-nyc-neuromodulation-conference/index.html

Looking further ahead:

• Cognitive Computational Neuroscience (CCN) Annual Conference, August 6th: CCN is an annual forum for discussion among researchers in cognitive science, neuroscience, and artificial intelligence, dedicated to understanding the computations that underlie complex behavior. Find out more here: https://2026.ccneuro.org/

• NeuroNYC x Precision Neuroscience Event, August 20th: Are you a student or an early-career professional looking to break into the neurotech industry? Save the date for an evening on building your career in brain-computer interfaces with Joel Greengrass, Chief People Officer at Precision Neuroscience. Keep an eye out for more details.

• Check out our LinkedIn to stay updated: https://www.linkedin.com/company/neuronyc

NeuroNYC News:

• To further support our community-building efforts, we are fundraising. If you are interested in sponsoring NeuroNYC for future events, please contact George Kenefati: george@neuro-nyc.org

Neurotech News in NYC:

• Precision Neuroscience and Synchron: New roles listed!

• Mount Sinai’s NYBCI Symposium: Returns November 4-6. Speaker proposals are open through July 31: https://bit.ly/NYBCI26-cfp

• Mount Sinai: Researchers show DBS can remodel brain wiring and drive brain-wide functional changes in depression. Read more here.

For the curious souls who want to read more neurotech newsletters:

• For those curious about keeping up with the fast-advancing neurotechnology landscape, Neurotech Notables by Naveen Rao is the biweekly newsletter covering everything moving in neurotech including funding, breakthroughs, industry shifts, and the deals you’ll be hearing about next:

NEUROTECH FUTURES

The #1 neurotechnology industry newsletter in the world. Join our ecosystem for news, analysis, jobs, events, & more!

By Naveen Rao

• Chay Carter and Max Kelly have co-founded Reccy Neuro, a platform providing personalized recruiting for neurotech jobs. Check out their newsletter:

The Neurotech Newsletter

The Neurotech Newsletter, brought to you by Carter Sciences. We share bi-weekly updates on Funding, Regulatory, Clinical, Launches and Hiring news. Subscribe for full articles and analysis

By Chay’s Neurotech Newsletter

Until next time,

Fargol Yeganeh Fathi

Head of Academic Partnerships @ NeuroNYC

Across the five boroughs, Long Island, the Hudson Valley, northern New Jersey, and western Connecticut, the metro region is home to more than 5,000 life sciences businesses, the most of any U.S. metro region, leading the Boston region by 30%. Key players include universities like NYU, Columbia, Rockefeller University, Rutgers, Princeton, Yale, and the CUNYs, hospitals like NYU Langone, New York-Presbyterian Weill Cornell, Mt. Sinai, Montefiore Einstein, and Northwell Health, and institutions like the New York Genome Center, the New York State Psychiatric Institute, and the Nathan Kline Institute. Together, these groups received $3.3 billion in NIH funding in 2024, the most federal funding given to life sciences groups in any U.S. metro region. The region is also home to major life sciences companies like Pfizer, Regeneron, Johnson & Johnson, Roivant, Axsome Therapeutics, and Bristol-Myers Squibb.

Despite a density of talent in the region, New York City’s life sciences startup ecosystem is just starting up. Back in 2014, New York City life sciences startups raised only $50 million in venture capital (VC) funding. Two years later, recognizing economic potential, the city announced LifeSci NYC, a $1 billion commitment to life sciences in the five boroughs. The initiative has focused on increasing square footage of lab space for startups and providing resources to accelerate growth. In 2018, Johnson & Johnson opened JLABS @ NYC in SoHo, a life sciences startup incubator, with help from the city; in 2022, the city cut the ribbon on the Taystee Building in West Harlem, providing lab space for life sciences research groups like Harlem Biospace and a CCNY startup incubator; in 2023, the city committed to build SPARC Kips Bay, a development five times the square footage of the Taystee Building, which will provide more parceled lab space, along with space for New York state and city schools. Besides infrastructure, the city has promoted innovation with credit and resources: in 2018, LifeSci NYC introduced an expansion fund to provide loans and guidance to Seed and Series A life sciences startups; in 2022, the city introduced a yearly Founder Fellowship; in 2023, then-Mayor Eric Adams passed a biotech tax credit designed to benefit early-stage biotech startups.

The city’s life sciences startups responded, and VCs got the memo. A decade later, New York City life sciences startups raised $1.8 billion — 25 times their 2014 total, adjusted for inflation. $2 billion was raised by life sciences startups across the greater metro region that year, the fourth-most among U.S. metro regions. To the city, its investments have been a success, seeing the metro region’s life sciences economic output compound 8% annually from 2014 to 2024, leading the city’s total rate of 2% over that time. The life sciences sector saw a 70.9% GDP growth from 2019 to 2024, doubling that of Finance & Insurance.

The strength of the local life sciences industry and the growth of its startup ecosystem are good proxies for expected growth of many of the most valuable neurotech firms to come: those developing clinical and implanted neurotech, who will draw on much of the same research talent pool as pharma and biotech firms, and whose products will require the same investor resilience to FDA hurdles and extended timelines to revenue. As expected, such neurotech firms have participated in the growth: Synchron, which places a stent electrode in an artery of the brain for computer interfacing, was incorporated in 2016 in Brooklyn and recently reached a $1 billion valuation with a Series D fundraiser of $345 million; Precision Neuroscience, which places electrodes under the scalp for computer interfacing, was founded in Manhattan in 2021 and has raised $155 million in four rounds of funding since.

But for neurotech companies that are not implanting devices or promising medical benefits — imagine Õura using neural data to generate health suggestions, or a company building software and hardware for other neurotech groups — the health of the local tech sector is another good proxy for estimated growth. And, like the life sciences, the local tech startup ecosystem has come into form relatively recently. Recognizing a lag behind other cities’ tech economies in the early 2010s, the city led initiatives to bolster local tech: in 2008, the city started NYC Seed, a VC firm which invested in seed-stage tech startups until 2015, and in 2010 the city gave $100 million to Cornell University to help build Cornell Tech, a graduate tech campus and startup incubator, on Roosevelt Island, which spurred NYU and Columbia to found data science graduate programs soon after. In 2010 Google moved into Chelsea, and in 2012 Facebook opened its first engineering operation beyond the West Coast in Midtown.

These developments brought New York tech up to speed, and by the 2020s it was ready for the A.I. boom, as the percentage of the city’s total VC investments going to local tech startups from 2019 to 2024 grew from 37.6% to 52.4% while the sector saw 54.2% GDP growth, and 35 A.I.-related local startups have reached $1 billion valuations. Those non-implanted, non-clinical neurotech startups saw growth in the same years: CTRL Labs, which uses wrist-based motor signal electrodes for device control, was founded in Midtown in 2015 and then acquired by Meta in 2019 for up to $1 billion (Meta subsequently opened their first New York-based Reality Labs office in its place); Synaptrix Labs, which uses wearable electrodes for computer interfacing, was founded in Manhattan in 2023 and secured up to $10 million in seed funding from Mark Cuban Companies just one year later.

In an environment where world-class scientists and engineers are trained around every corner, startup infrastructure and acceleration have become a public priority, and VCs continue to invest more heavily into life sciences and tech, the New York metro region is well positioned to lead neurotech innovation in coming years.

As a global leader in research, medicine, tech, finance, and policy, the New York metro region is well-positioned to lead neurotech. 5,000+ life science businesses across the five boroughs, Long Island, the Hudson Valley, northern New Jersey, and western Connecticut raised $2 billion in venture capital and received $3.3 billion in NIH funding in 2024 — that’s the most life sciences businesses with the fourth-most VC funding and the most federal funding for the sector across U.S. metro regions. New York City’s startup ecosystem is recognized as #2 globally with a collective valuation of $621 billion, driven by a rising tech sector. Upstate, Albany is at the forefront of the tech policy conversation with its 2025 RAISE Act.

Recognizing the region’s potential, NeuroNYC was founded in 2022 by a group of researchers, engineers, and founders from Sharper Sense, OpenBCI, Synchron, NYU, Columbia University, Cornell Tech, Meta, and Apple on three goals: Community Orchestration, to bridge gaps between hubs of the local neurotech industry; Regional Advocacy, to amplify awareness for neurotech in the New York region; and Ethical Stewardship, to increase transparency of the local ecosystem to ethically guide progress.

Towards these goals, we organize events bringing together key hubs. We began in 2023 with a handful of happy hours at leading local neurotech developers like Synchron and OpenBCI, a tradition that has been ongoing quarterly since. Between these, we held a symposium at Brown Rudnick LLP, where panelists from Columbia, NYU, IBM, and Brainify.AI joined Bay Area counterparts from Stanford, UCSF, and Meta to discuss progress towards neural foundation models for AI; we hosted NeuroBall, a black-tie gala joining industry, law, policy, and VC, sponsored by OpenBCI, Synchron, and Cooley LLP; and we held a Summer Summit with Solomon Partners and Boston Consulting Group, where panelists from Neuvotion, Northwell Health, and Jumpspace VC discussed the state of commercialization of neurotech. (Our next Summer Summit was recently announced — request an invitation for your group!)

Digitally, we streamline resources to help navigate the ecosystem: we’ve created an ecosystem tracker that lists and visualizes companies, labs, clinics, and funders in the metro region; we broadcast trials, products, and papers coming from these groups; our job page centralizes their career openings; and our NeuroNYC Wire collects relevant headlines across local media.

Now, we’re excited to continue promoting the local neurotech ecosystem here, with our Substack. We’ll use our proximity to New York neurotech R&D, policymaking, and markets to bring developing stories to light, engaging with discourse and key figures in the neurotech world. Stay tuned next week for our first article and regular content going forward from then.

Who are we? We are NeuroNYC, and our mission is to cultivate the neurotech community within the NYC area. We bring together founders, researchers, clinicians, investors, operators, artists, and policymakers across the entire neurotech ecosystem; spanning BCIs, neuromodulation, digital health, AI-driven neuroscience, and more.

Our goal is simple: build a high-signal, human-scale community that helps neurotech move from the lab to real-world impact.

🌷 April Recap

• NeuroNYC is thrilled to introduce our official Advisory Board; a powerhouse group of leaders across academia, industry, venture capital, and law. https://neuro-nyc.org/advisory-board

• April was a great month for the NeuroNYC community. We joined the NY Tech Alliance event, where attendees explored cutting-edge neurotech demos including a showcase from our own Charlie Rodenkirch, CEO of Sharper Sense. We closed out the month with a packed happy hour, full of great conversations and connections. As the weather improves, look out for more outdoor events on the horizon.

🗓️ NeuroNYC Event

No May events! Here is the list of our June events for NY Tech Week:

• The Neural Network Mixer; June 4th, Thursday: Join us for NeuroNYC’s NeuroAI fireside chat + mixer, where the brightest minds in neurotech, AI, and brain-computer innovation come together. RSVP on Partiful: https://partiful.com/e/YMW6sYTh9iRAZZnDCycn

• NeuroNYC Central Park Walk and Talk; June 7th, Sunday: Join us for a walk as a chance to connect with fellow neurotech enthusiasts! Previous events included attendees from: OpenBCI, Synchron, Sharper Sense, Mount Sinai, etc. RSVP on Partiful: https://partiful.com/e/vTr6qDDFC1zHFdKZbtgk

Looking further ahead:

• NeuroNYC x Precision Neuroscience Event; August 20th, Thursday: Are you a student or an early-career professional looking to break into the neurotech industry? Save the date for an evening on building your career in brain-computer interfaces with Joel Greengrass, Chief People Officer at Precision Neuroscience. Keep an eye out for more details.

• Check our LinkedIn to stay updated: https://www.linkedin.com/company/neuronyc

• Tune in to our monthly newsletter for upcoming events. In the meantime, you can always find upcoming events on our calendar: https://neuro-nyc.org/calendar

🧠 NeuroNYC News

• NYC Neuromodulation Conference, July 30–Aug 3: NeuroNYC is an official partner of the conference and is offering an exclusive community discount. Register with code NEURONYCX26; abstract submissions are open through May 30, 2026: https://neuromodec.org/2026-nyc-neuromodulation-conference/index.html

• To further support our community-building efforts, we are fundraising. If you are interested in sponsoring NeuroNYC for future events, please contact George Kenefati: george@neuro-nyc.org

🗽 Neurotech News in NYC! 

• Mount Sinai: The Icahn School of Medicine at Mount Sinai announced enrollment of the first patient in a U.S. Department of Defense-funded clinical trial testing whether SAINT®, an FDA-cleared non-invasive treatment for major depressive disorder (MDD), can safely and rapidly relieve symptoms of postpartum depression. Click to read more.

• Columbia University: Columbia Engineering has detailed a flexible brain-computer interface chip (BISC) that combines dense neural recording, stimulation, telemetry, and wireless power on one implantable substrate. Click to read more.

• Radial: Radial, a psychiatric neuromodulation clinic, expands to seven clinics with a new location in Brooklyn, Williamsburg. Click to read more.

🌍 Neurotech News in the World

• For those curious about keeping up with the fast-advancing neurotechnology landscape: Neurotech Notables by Naveen Rao is the biweekly newsletter covering everything moving in neurotech; funding, breakthroughs, and industry shifts. Subscribe to his Substack to join the newsletter:

NEUROTECH FUTURES

The #1 neurotechnology industry newsletter in the world. Join our ecosystem for news, analysis, jobs, events, & more!

By Naveen Rao

Until next time,

Fargol Yeganeh Fathi

Head of Academic Partnerships @ NeuroNYC

Who are we? We are NeuroNYC, and our vision is to make New York the neurotech capital of the world. We bring together founders, researchers, clinicians, investors, operators, artists, and policymakers across the entire neurotech ecosystem; spanning BCI, neuromodulation, digital health, AI-driven neuroscience, and more.

Our goal is simple: build a high-signal, human-scale community that helps neurotech move from the lab to real-world impact.

🌷 March Recap

• On March 26th, we convened in Times Square Tower for an evening at the frontier of neuroscience and AI, focused on Brain Foundation Models; large-scale systems trained on diverse neural data to capture and generalize brain function. Bringing together leading researchers and builders across academia and industry, the symposium sparked sharp discussions on scaling, generalization, and real-world deployment, from clinical diagnostics to BCIs. Credit to Margot Hanley and Peter Zhegin for creating one of the most intellectually vibrant rooms in NYC. This event is the launch of the Neuro AI initiative. Tune in for more events to come: https://margothanley.github.io/neuroai-initiative/

🗓️ NeuroNYC Events

• April 13th, Monday; NY Tech Meetup for Neuro + Health Tech: Bringing together founders, researchers, clinicians, engineers, and investors for live demos and conversations at the forefront of neurotechnology and the future of human health. Use code JZ5HCL: https://luma.com/w9gryh4r

• April 14th, Tuesday; Bioelectronic Medicine Forum: Bioelectronic Medicine Forum featuring keynote Michel Maharbiz (iota Biosciences) unveiling Epia Neuro, alongside leaders from neuroloop, Spiro Medical, and more. NeuroNYC members registering after April 6 receive $300 off: https://www.neurotechreports.com/pages/registerbmf-NYCNeuro.html

• April 21st, Tuesday; NeuroNYC Happy Hour: Join for a fun evening of networking and mingling with people in the neurotech field. Register here: https://luma.com/tr40n26d

• Check our LinkedIn to stay updated: https://www.linkedin.com/company/neuronyc

• Tune in to our monthly newsletter for upcoming events. In the meantime, you can always find upcoming events on our calendar: https://neuro-nyc.org/calendar

🧠 NeuroNYC News

• NYC Neuromodulation Conference, July 30–Aug 3: NeuroNYC is an official partner of the conference and is offering an exclusive community discount. Register with code NEURONYCX26; abstract submissions are open through May 30, 2026: https://neuromodec.org/2026-nyc-neuromodulation-conference/index.html

• To further support our community-building efforts, we are fundraising. If you are interested in sponsoring NeuroNYC for future events, please contact George Kenefati: george@neuro-nyc.org

💼 Neurotech Job Board in NYC

• City College of New York; Parra Lab: Hiring for Summer 2026; 2 undergraduate and 2 high school students to work on VR-based neuroscience data (EEG, eye/head movement, memory); analysis-focused. Apply by sending a CV to parra@ccny.cuny.eduand vraghavan@ccny.cuny.edu

🗽 Neurotech News in NYC!

• Synaptrix: is recruiting participants for a 90-minute session ($50 compensation) using a research headset to record brain activity. The goal: building a non-invasive brain-computer interface that lets users steer a wheelchair using only imagined movement. Sign up here: https://calendly.com/synaptrix/data-collection

Until next time,

Fargol Yeganeh Fathi

Head of Academic Partnerships @ NeuroNYC

Who are we? We are NeuroNYC, and our vision is to make New York the neurotech capital of the world. We bring together founders, researchers, clinicians, investors, operators, artists, and policymakers across the entire neurotech ecosystem; spanning BCI, neuromodulation, digital health, AI-driven neuroscience, and more.

Our goal is simple: build a high-signal, human-scale community that helps neurotech move from the lab to real-world impact.

❄️ February Recap

• State of jobs in NeuroNYC: Conor Russomanno (Founder & CEO, OpenBCI) and Chay Carter(Founder, Carter Sciences) joined Margot Hanley, PhD for a candid conversation on what it actually takes to build neurotech teams today - from the realities of assembling a founding team to the talent gaps and hiring challenges shaping the field right now, especially here in NYC.

🗓️ NeuroNYC Events

• March 26, Thursday; e184 x NeuroNYC: There will be limited space available for an evening symposium organized around the rapidly developing field of foundation models for the brain.

• Mid April, NeuroNYC Happy Hour: be on the lookout for an upcoming HH. Check our LinkedIn to stay updated: https://www.linkedin.com/company/neuronyc

• Tune in to our monthly newsletter for upcoming events. In the meantime, you can always find upcoming events on our calendar: https://neuro-nyc.org/calendar

🧠 NeuroNYC News

• We’re hosting an invite-only curated GP/LP lunch and we’re looking for sponsor(s) to cover the cost of lunch. For details or questions, reach out to Paul Brezovsky III - pjb9875@nyu.edu.

• To further support our community-building efforts, we are fundraising. If you are interested in sponsoring NeuroNYC for future events, please contact George Kenefati: george@neuro-nyc.org

💼 Neurotech Job Board in NYC

• Egra has raised $5.5M to build EEG foundation models and is hiring: https://jobs.ashbyhq.com/Egra

• OpenBCI has new openings: https://openbci.com/careers

🗽 Neurotech News in NYC!

• Chay Carter and Max Kelly have co-founded Reccy Neuro, a platform providing personalized recruiting for neurotech jobs. Check out their newsletter:

The Neurotech Newsletter

The Neurotech Newsletter, brought to you by Carter Sciences. We share bi-weekly updates on Funding, Regulatory, Clinical, Launches and Hiring news. Subscribe for full articles and analysis

By Chay’s Neurotech Newsletter

• Walter Koroshetz Joins the Dana Foundation as a Senior Advisor: The Dana Foundation is headquartered in New York City and is a major brain research philanthropy.

Until next month,

Fargol Yeganeh Fathi

Who are we? We are NeuroNYC, and our vision is to make New York the neurotech capital of the world. We bring together founders, researchers, clinicians, investors, operators, artists, and policymakers across the entire neurotech ecosystem; spanning BCI, neuromodulation, digital health, AI-driven neuroscience, and more.

Our goal is simple: build a high-signal, human-scale community that helps neurotech move from the lab to real-world impact.

We’re very excited about the year ahead and the innovations to come.

NeuroNYC Events

Riding on the high of the neurotech community building spirit from our last event in December, our annual NeuroBall (picture attached), we will continue our events:

• Feb 12th, Thursday; NeuroNYC Fireside Chat + Happy Hour: The State of Jobs in Neurotech. Sign up through our Luma link: https://luma.com/fims30t8

• NeuroNYC takes over Paris the week of Feb 22nd: In parallel with the International Association for Safe & Ethical AI annual conference, we’ll be hosting a neurotech happy hour in Paris. More details coming soon on LinkedIn. Spread the word to your neurotech friends in Paris!

• Tune in to our monthly newsletter for upcoming events. In the meantime, you can always find upcoming events on our calendar: https://neuro-nyc.org/calendar

NeuroNYC News

• We are excited to announce that we have launched our resources for navigating NYC’s neurotech ecosystem in academia, industry, medical settings, and neurotech funders. Check it out: https://neuro-nyc.org/ecosystem-tracker

• NeuroNYC is looking for a volunteer! Are you passionate about social media strategy, content, and community engagement? We’re looking for someone to manage and grow our Instagram and LinkedIn presence.

Email us: hello@neuro-nyc.org

Don’t forget to follow us on LinkedIn: https://www.linkedin.com/company/neuronyc

Neurotech News in NYC!

• Northwell Health has launched a new Center for Psychedelics Research and Treatment, underscoring New York’s expanding footprint in frontier psychiatric care and translational neurotech. As momentum builds across clinical systems and early-stage infrastructure, NYC continues to strengthen its role as a hub for brain-health innovations.

See you next time!